GRANTS FUNDED in 2009
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2009 Funding Decisions
Click here to begin your search
for research updates by HDF-funded scientists and others.
PubMed, a service of the National Library of Medicine, provides access to
over 12 million MEDLINE citations back to the mid-1960's and additional life
science journals.
PubMed includes links to many sites providing full text articles and other
related resources.
Hereditary Disease Foundation grants, postdoctoral fellowships and research contracts are helping to find treatments and cures for Huntington’s disease and other similar hereditary disorders. The HDF’s Scientific Advisory Board, comprised of world-renowned experts in genetics, neurology, neuroscience, and drug therapy development, meets three times each year to review and approve funding for groundbreaking research.
RESEARCH GRANTS
Wenzhen Duan
Johns Hopkins University School of Medicine
Exploration of SIRT1 as a potential target for HD treatment in mouse models of Huntington’s disease.
Karine Merienne
IGBMC, Cedex, France
Role of the DNA damage response in Huntington's disease.
Daniel Offen
Tel Aviv University, Tel Aviv, Isreal
Mesenchymal stem cells secreting neurotrophic factors: a potential new therapy for Huntington’s disease.
Alexander Osmand
University of Tennessee
Oligodendrocyte Dysregulation in Huntington’s disease.
Masahito Shimojo
University of Kentucky Research Foundation
Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s disease.
POSTDOCTORAL FELLOWSHIPS
Ismael Al-Ramahi
Baylor College of Medicine, Houston, TX
Mentor: Juan Botas
Screen of genes involved in Ca2+ homeostasis and signaling to identify genetic modifiers and potential targets for HD treatment.
Elodie Bruel-Jungerman
University of Rochester
Mentor: Steven Goldman
Can AAV4-BDNF/Noggin induce striatal neurogenesis and delay symptoms in R6/2 HD mice?
Geraldine Gomez
Children’s Hospital Boston
Mentor: Paul Rosenberg
The Role of Cell-Type Specific Expression of GLT1 in the Pathogenesis of Huntington’s disease.
Raphael Hourez
Harvard Medical School
Mentor: Alfred Goldberg
Can puromycin-sensitive aminopeptidase (PSA) help protect against polyglutamine-induced neurodegeneration?
Jane E. Lauckner
Stanford University
Mentor: Ron Kopito
Characterization of the infectious transmission of polyglutamine aggregates in the pathogenesis of Huntington’s disease.
RESEARCH CONTRACTS
Christian Néri
INSERM, Paris, France
Accelerating data integration for the prioritization of HD high-quality neuroprotective targets and releasing information.
Leslie M. Thompson and J. Lawrence Marsh
University of California, Irvine
Role of SUMOylation, T3 phosphorylation and altered protein interactions influenced by post-translational modification in HD pathogenesis.
with
Joan S. Steffan
University of California, Irvine
The IKK complex phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome.
|
